Merus raised a round of funding on January 17, 2006. Investors include Aglaia Biomedical Ventures.

Merus is a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, referred to as Biclonics. Biclonics are based on the full-length IgG format, are manufactured …